News

According to Oragenics, IVIAT is a unique discovery platform designed to identify genes of pathogenic bacteria that are specifically present when humans have infections. Robert Zahradnik, president and

The study is designed to evaluate the safety and efficacy of ACP-104 in patients with schizophrenia who are experiencing an acute psychotic episode. A total of 248 patients

Under the terms of the collaboration, Alba will receive an initial, non- refundable licensing payment of $25 million. Joint development costs toward global approval of AT-1001 will be

This was the eighth of several regularly scheduled reviews by the Data Safety Monitoring Board (DSMB), including the planned in-depth interim safety analysis, held in April 2007, on

The lawsuit asserts that Watson’s Quasense product infringes Duramed’s US patent number 5,895,032. Watson launched its Quasense product in September 2006 following the FDA’s final approval of its

Wayne Danter, president and chief scientific officer of Critical Outcome Technologies (COTI), said: “Over the last 12 months COTI has made considerable progress in advancing our product pipeline

Whether the complete response and this supplemental submission resolve to the FDA’s satisfaction the issues raised in the approvable letter is not yet known, said Wyeth. The current

At a median follow-up of 100 months, more than three years after the completion of treatment, Arimidex significantly reduced the risk of recurrence in comparison with tamoxifen in

Ocimum has assumed certain liabilities associated with the genomics assets and business. The Gene Logic name transfers to Ocimum Biosolutions and the company, formerly named Gene Logic, now